60 degrees pharma plans pivotal babesiosis study with tafenoquine following jan 17 fda meeting

Post-fda meeting, 60 degrees pharma plans pivotal study of tafenoquine in hospitalized babesiosis patients, aiming to start in summer 2024. #biotech #sxtp

SXTP Ratings Summary

SXTP Quant Ranking